Effect of Treatment With Candesartan or Enalapril on Subcutaneous Small Artery Structure in Hypertensive Patients With Noninsulin-Dependent Diabetes Mellitus

Structural alterations of subcutaneous small resistance arteries are associated with a worse clinical prognosis in hypertension and noninsulin-dependent diabetes mellitus (NIDDM). However, no data are presently available about the effects of antihypertensive therapy on vascular structure in hypertensive patients with NIDDM. Therefore, we have investigated the effect of an angiotensin-converting enzyme inhibitor, enalapril, and a highly selective angiotensin receptor blocker, candesartan cilexetil, on indices of subcutaneous small resistance artery structure in 15 patients with mild hypertension and NIDDM. Eight patients were treated with candesartan (8 to 16 mg per day) and 7 with enalapril (10 to 20 mg per day) for 1 year. Each patient underwent a biopsy of the subcutaneous fat from the gluteal region at baseline and after 1 year of treatment. Small arteries were dissected and mounted on a micromyograph and the media-to-internal lumen ratio was evaluated; moreover, endothelium-dependent vasodilation to acetylcholine was assessed. A similar blood pressure-lowering effect and a similar reduction of the media-to-lumen ratio of small arteries was observed with the 2 drugs. Vascular collagen content was reduced and metalloproteinase-9 was increased by candesartan, but not by enalapril. Changes of circulating indices of collagen turnover and circulating matrix metalloproteinase paralleled those of vascular collagen. The 2 drugs equally improved endothelial function. In conclusion, antihypertensive treatment with drugs that inhibit the renin-angiotensin-aldosterone system activity is able to correct, at least in part, alterations in small resistance artery structure in hypertensive patients with NIDDM. Candesartan may be more effective than enalapril in reducing collagen content in the vasculature.

[1]  M. Mulvany,et al.  Dual Processes of Remodeling and Growth , 2005 .

[2]  E. Porteri,et al.  Acromegalic Patients Show the Presence of Hypertrophic Remodeling of Subcutaneous Small Resistance Arteries , 2004, Hypertension.

[3]  E. Schiffrin,et al.  Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment , 2004, Hypertension.

[4]  Giuseppe Mancia,et al.  Looking back, looking forward , 2004 .

[5]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. , 2004, Hypertension.

[6]  C. de Ciuceis,et al.  Prognostic Significance of Small-Artery Structure in Hypertension , 2003, Circulation.

[7]  D. Rizzoni.  2504 Small artery structure may predict outcome in hypertension , 2003 .

[8]  E. Porteri,et al.  Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. , 2003, Journal of hypertension.

[9]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[10]  IanSchofield,et al.  Vascular Structural and Functional Changes in Type 2 Diabetes Mellitus , 2002 .

[11]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[12]  L. Fratta,et al.  Cardiovascular Influences of &agr;1b-Adrenergic Receptor Defect in Mice , 2002, Circulation.

[13]  E. Schiffrin,et al.  Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function , 2002, Journal of hypertension.

[14]  Arantxa González,et al.  Biochemical assessment of myocardial fibrosis in hypertensive heart disease. , 2001, Hypertension.

[15]  Ernesto L. Schiffrin,et al.  Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis , 2001, Hypertension.

[16]  Arantxa González,et al.  Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients , 2001, Circulation.

[17]  E. Schiffrin,et al.  Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension , 2001, Journal of hypertension.

[18]  E. Porteri,et al.  Structural Alterations in Subcutaneous Small Arteries of Normotensive and Hypertensive Patients With Non–Insulin-Dependent Diabetes Mellitus , 2001, Circulation.

[19]  E. Schiffrin,et al.  Structure and Mechanical Properties of Resistance Arteries in Hypertension: Role of Adhesion Molecules and Extracellular Matrix Determinants , 2000, Hypertension.

[20]  J. Emparanza,et al.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.

[21]  E. Schiffrin,et al.  Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. , 2000, Circulation.

[22]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[23]  M. Cooper,et al.  Cellular mechanisms of diabetic vascular hypertrophy. , 1999, Microvascular research.

[24]  J. Díez,et al.  Abnormalities of the extracellular degradation of collagen type I in essential hypertension. , 1998, Circulation.

[25]  E. Schiffrin,et al.  How to assess vascular remodelling in small and medium‐sized muscular arteries in humans , 1997, Journal of hypertension.

[26]  R. Zulli,et al.  Effects of long‐term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy , 1997, Journal of hypertension.

[27]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[28]  E. Porteri,et al.  Vascular hypertrophy and remodeling in secondary hypertension. , 1996, Hypertension.

[29]  R. Zulli,et al.  Cardiac and vascular structural changes. Prevalence and relation to ambulatory blood pressure in a middle-aged general population in northern Italy: the Vobarno Study. , 1996, Hypertension.

[30]  M. Mulvany,et al.  Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. , 1995, Hypertension.

[31]  E. Schiffrin,et al.  Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. , 1995, American journal of hypertension.

[32]  E. Schiffrin,et al.  Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. , 1994, Hypertension.

[33]  M. Mulvany.  Vascular remodelling in hypertension. , 1993, European heart journal.

[34]  M. Mulvany,et al.  Small artery structure in hypertension. Dual processes of remodeling and growth. , 1993, Hypertension.

[35]  M. Mulvany,et al.  Structure and function of small arteries. , 1990, Physiological reviews.

[36]  M. Mulvany,et al.  Direct Evidence that the Greater Contractility of Resistance Vessels in Spontaneously Hypertensive Rats is Associated with a Narrowed Lumen, a Thickened Media, and an Increased Number of Smooth Muscle Cell Layers , 1978, Circulation research.

[37]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.